Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | TLR3 | O15455 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | STAT6 | P42226 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL8427098 | 0.89 | KIT (0.80) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL24276985 | 0.89 | KIT (0.80) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL9678963 | 0.87 | KIT (0.77) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL5309123 | 0.86 | KDM4E (0.76) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL11831488 | 0.85 | KIT (0.74) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL10507648 | 0.84 | KIT (0.73) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL26836186 | 0.84 | KIT (0.73) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL17212473 | 0.84 | KIT (0.76) | KITRECQLKDM4EMEN1MAPT | |
| Hydrochloric Acid SCHEMBL11068466 | 0.83 | KIT (0.71) | KITRECQLKDM4EMEN1MAPT | |
| SCHEMBL8821045 | 0.83 | KIT (0.71) | KITRECQLKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016254-A2 | ANTINEOPLASTIC ACTIVITIES OF ELLIPTICINE AND ITS DERIVATIVES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027175-A1 | Antineoplastic activities of ellipticine and its derivatives | SHAUGHNESSY JOHN JR | 2007-02-01 | — | — | US | claimed |
| EP-0345171-B1 | Metalloporphyrine derivatives, their therapeutical use and their use in the preparation of hybrid molecules | CENTRE NAT RECH SCIENT (FR) | 1995-12-13 | — | — | EP | claimed |
| EP-0345171-A1 | Metalloporphyrine derivatives, their therapeutical use and their use in the preparation of hybrid molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-12-06 | — | — | EP | claimed |
| US-4045565-A | TREATING LEUKEMIAS, TUMORS, AND CARDIAC DISORDERS; DEMETHYLATING A 9-METHOXY-ELLIPTICINE WITH PYRIDINE HYDROCHLORIDE | ETABLISSEMENT PUBLIC DIT: AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1977-08-30 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-115650973-B | Synthesis method and application of NSC69187 derivative compound | 南方医科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| CN-115650973-A | NSC69187 and synthesis method and application of derivative thereof | 南方医科大学 | 2023-01-31 | — | — | CN | disclosed |
| EP-0173462-A2 | Ellipticine derivative and production process thereof | SUNTORY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
| US-4483989-A | BENZOYLATION 6-HYDROXYCARBAZOLE, FORMYLATING, CYCLIZATION, AND SAPONIFICATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1984-11-20 | — | — | US | disclosed |
| US-4444776-A | ANTITUMOR, ANTIVIRAL | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (A N V A R) (FR) | 1984-04-24 | — | — | US | disclosed |
| US-4434290-A | TREATMENT OF LEUKEMIAS | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (FR) | 1984-02-28 | — | — | US | disclosed |
| US-4310667-A | TREATMENT OF LEUKEMIA AND SOLID TUMORS | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1982-01-12 | — | — | US | disclosed |
| US-4266060-A | ANTITUMOR ANTIVIRAL AGENTS FOR TREATMENT OF CANCER | AGENCE NATIONALE DE VAL ORISATION DE LA RECHERCHE (ANVAR) (FR) | 1981-05-05 | — | — | US | disclosed |
| US-4045565-A | TREATING LEUKEMIAS, TUMORS, AND CARDIAC DISORDERS; DEMETHYLATING A 9-METHOXY-ELLIPTICINE WITH PYRIDINE HYDROCHLORIDE | ETABLISSEMENT PUBLIC DIT: AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1977-08-30 | — | — | US | disclosed |
| US-3933827-A | CYTOSTATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | KIT 4611/4885RECQL 396/4885KDM4E 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.